Chrysophanein of Rhubarb Rescues ILC3-Derived IL-22 by Blocking CCDC25/ILK/HIF-1α for Mucosal Healing in Ulcerative Colitis Mice
简介:
- 作者: Bo Xu, Shuiling Cao, Chunjing Li, Meng Zhao, Qing Wang, Xueqian Xie, Hongxu Chen, Rui Xu, Qi Yi, Xuezhou Ke, Ying Zhu, Lian Zhou, Xia Luo
- 杂志: Journal of Ethnopharmacology
- Doi: https://www.doi.org/10.1016/j.jep.2025.120628
- 出版日期: 2025/9/22
摘要
Ethnopharmacological relevance: In traditional Chinese medicine, rhei radix et rhizoma, is derived from the dried roots and rhizomes of Rheum palmatum L., Rheum tanguticum Maxim. ex Balf. or medicinal Rheum officinale Baill, are used to treat intestinal carbuncle and abdominal pain, as well as damp-heat dysentery. Chrysophanein is a natural compound extracted from rhei radix et rhizoma with significant anti-inflammatory properties.
Aim: Ulcerative colitis (UC) is characterized by chronic mucosal inflammation. Current therapies alleviate symptoms via anti-inflammatory effects but fail to prevent relapse. Restoring the intestinal mucosal barrier represents a novel therapeutic strategy beyond conventional approaches. This study aims to show that chrysophanein ameliorates UC symptoms by targeting the coiled-coil domain containing protein 25/integrin-linked kinase/hypoxia-inducible factor-1α(CCDC25/ILK/HIF-α) pathway to repair mucosal barrier integrity.
Methods: We established a CCDC25-overexpressing UC mouse model through the intraperitoneal injection of adeno-associated virus (AAV)-CCDC25, alongside providing the mice with free access to dextran sulfate sodium(DSS). Disease progression was evaluated through body weight, survival status, colon length, endoscopy, and histopathology. chrysophanein-treated UC mice were assessed via Alcian blue staining (mucin quantification), WB (Occludin/ZO-1/claudin-1), in vivo imaging (FITC-dextran 4000 distribution), limulus amebocyte lysate assay (serum LPS), bacterial translocation assays, WB (CCDC25/ILK/HIF-1α pathway), and flow cytometry (IL-22+ILC3s). Transmission electron microscopy (TEM) evaluated epithelial morphology, and co-culture experiments examined chrysophanein's protective effects on enterocytes.
Results: Compared to control AAV-UC mice, CCDC25-overexpressing mice exhibited exacerbated symptoms. chrysophanein significantly attenuated weight loss, hematochezia, and colon damage, enhanced mucosal barrier function (mucin, ZO-1/Occludin/Claudin-1), reduced bacterial translocation and serum LPS, suppressed CCDC25/ILK/HIF-1α, and elevated IL-22+ILC3 proportions in UC mice. However, CCDC25 overexpression diminished chrysophanein's efficacy, correlating with reduced IL-22+ILC3s. chrysophanein-MNK3-conditioned media increased TEER, lowered FD4 permeability, and upregulated ZO-1 (mimicking IL-22 recombinant protein), whereas OECCDC25-MNK3 media reversed these effects, confirming CCDC25's overexpression interferes with chrysophanein-mediated intestinal epithelial barrier repair via the IL-22 pathway.
Conclusion: Chrysophanein rescues ILC3-derived IL-22 by blocking CCDC25/ILK/HIF-1α for mucosal healing in UC.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。